We are live on ! Find out more
VTAE

VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE

Delisted

VTAE was delisted on the 24th of October, 2016.

Back to rankings

78 hedge funds and large institutions have $137M invested in VITAE PHARMACEUTICALS INC COMMON STOCK in 2016 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 19

13% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 16

3% more funds holding

Funds holding: 76 → 78 (+2)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

52% less capital invested

Capital invested by funds: $284M → $137M (-$148M)

Holders
78
Holders Change
+2
Holders Change %
+2.63%
% of All Funds
2.08%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
18
Increased
32
Reduced
19
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$11.4M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11.4M
3
CAM
Cormorant Asset Management
Massachusetts
+$10.1M
4
DCM
DAFNA Capital Management
California
+$5.4M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.32M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$8.82M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.8M
3
DCM
Driehaus Capital Management
Illinois
-$4.4M
4
PA
Perceptive Advisors
New York
-$3.62M
5
Millennium Management
Millennium Management
New York
-$3.61M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
76
Barclays
United Kingdom
$1K -$3.63K -399 -75%
CSS
77
Cubist Systematic Strategies
Connecticut
$1K +$809 +89 New
Geode Capital Management
78
Geode Capital Management
Massachusetts
$556 +$82.4K +9,059 +12%
O
79
OrbiMed
New York
– -$8.82M -487,400 Closed
DCM
80
Driehaus Capital Management
Illinois
– -$4.4M -242,905 Closed
PA
81
Perceptive Advisors
New York
– -$3.62M -200,000 Closed
CS
82
Candriam SCA
Luxembourg
– -$2.41M -133,000 Closed
SFM
83
Sphera Funds Management
Israel
– -$2.17M -120,000 Closed
OM
84
Opaleye Management
Massachusetts
– -$1.06M -58,500 Closed
ACM
85
Atika Capital Management
New York
– -$724K -40,000 Closed
TA
86
Teachers Advisors
New York
– -$385K -21,264 Closed
NC
87
Nexthera Capital
New York
– -$375K -20,720 Closed
PPA
88
Parametric Portfolio Associates
Washington
– -$191K -10,550 Closed
MLICM
89
Metropolitan Life Insurance Company (MetLife)
New York
– -$191K -10,535 Closed
RP
90
Rowlandmiller & Partners
Georgia
– -$457K -4,487 Closed
PAM
91
Panagora Asset Management
Massachusetts
– -$44K -2,409 Closed
Axa
92
Axa
France
– -$43K -2,376 Closed
CG
93
Colony Group
Massachusetts
– -$39K -2,173 Closed
TC
94
Travelers Companies
Minnesota
– -$22K -1,188 Closed
QT
95
Quantbot Technologies
New York
– +$1.03K +113 New
1 2 3
4

VTAE Hedge Fund Activity: Q1 2016 in Review

78 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) for Q1 2016, worth a combined $137M — down 52% from $284M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new VTAE positions and 16 closed out — a net gain of 2 holders — while 32 added to existing stakes and 19 trimmed.

The largest buyer was RA Capital Management, adding an estimated $11.4M. The largest seller was OrbiMed, exiting entirely with an estimated $8.82M sold.

  • 78 institutional investors held VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) as of Q1 2016, up from 76 in Q4 2015.
  • Funds reported $137M of VITAE PHARMACEUTICALS INC COMMON STOCK stock for Q1 2016, down 52% quarter-over-quarter.
  • 18 funds opened new VITAE PHARMACEUTICALS INC COMMON STOCK positions in Q1 2016 and 16 closed out, a net change of +2 holders.
  • The largest VITAE PHARMACEUTICALS INC COMMON STOCK buyer in Q1 2016 was RA Capital Management, an estimated $11.4M added.
  • The largest VITAE PHARMACEUTICALS INC COMMON STOCK seller in Q1 2016 was OrbiMed, an estimated $8.82M sold.

Based on aggregated 13F filings for Q1 2016.